Core Viewpoint - The new generation information technology index on the Shanghai Stock Exchange's Sci-Tech Innovation Board has shown strong performance, with significant gains in key component stocks, indicating a bullish trend in the sector driven by advancements in AI and computing power. Group 1: Market Performance - As of September 30, 2025, the Sci-Tech Innovation Board's new generation information technology index rose by 1.71%, with component stocks such as Huahong Semiconductor up by 16.06% and Bawell Storage up by 9.10% [1] - The Sci-Tech Information Technology ETF (588100) also increased by 1.71%, reflecting active market trading with a turnover rate of 24.21% and a transaction volume of 85.38 million yuan [3] Group 2: Investment Trends - The AI industry is experiencing a high level of activity, with major players investing heavily in computing infrastructure, indicating a competitive landscape focused on securing resources for future AI advancements [4] - The demand for computing power and data flow is expected to grow significantly, as evidenced by the performance of the top ten weighted stocks in the index, which collectively account for 60.14% of the index [5] Group 3: Key Stocks and Their Performance - The top ten weighted stocks in the index include Cambricon, SMIC, and others, with varying performance; for instance, SMIC increased by 2.56% while Haiguang Information decreased by 1.13% [7] - The index components cover a wide range of sectors including chips, software, cloud computing, big data, and artificial intelligence, positioning it as a comprehensive investment vehicle in the AI landscape [7]

苏州纳微科技股份有限公司 简式权益变动报告书 上市公司名称：苏州纳微科技股份有限公司 股票上市地点：上海证券交易所 股票简称：纳微科技 股票代码：688690 信息披露义务人：陈荣华 住所：广东省深圳市福田区******** 通讯地址：广东省深圳市福田区******** 权益变动性质： 减少股份（减持）导致间接持股比例低于5% 签署日期：2025年9月29日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》、《上市公 司收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号- 权益变动报告书》及相关法律、法规和规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》及《公开 发行证券的公司信息披露内容与格式准则第 15 号—权益变动报告书》的规定， 本报告书已全面披露信息披露义务人在苏州纳微科技股份有限公司中拥有权益 的股份变动情况。 四、截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没 有通过任何其他方式 ...

证券代码：688690 证券简称：纳微科技 公告编号：2025-033 苏州纳微科技股份有限公司 关于持股 5%以上股东减持股份至 5%以下 的权益变动提示性公告 股东陈荣华保证向本公司提供的信息真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 本次权益变动为苏州纳微科技股份有限公司（以下简称"公司"）间接 持股 5%股东陈荣华先生减持通过深圳市纳微科技有限公司（以下简称"深圳纳 微"）间接持有的部分公司股份所致，不触及要约收购。 本次权益变动后，信息披露义务人陈荣华先生通过深圳纳微以及苏州纳 合管理咨询有限公司（以下简称"苏州纳合"）间接合计持有公司股份 20,189,661 股，占公司总股本比例为 4.9997%，不再是公司间接持股 5%以上股份 股东。 | 身份证号码 | 440103197004****** | | --- | --- | | 住所 | 广东省深圳市福田区******** | | 是否取得其他国家或地 | 否 | | 区的居留权 | | （二）本次权益变动情况 2025年9月22日至2025年9 ...

Core Viewpoint - Suzhou Nawei Technology Co., Ltd. announced that indirect shareholder Chen Ronghua reduced his stake in the company, dropping below the 5% threshold, which will not affect the company's control or governance [1] Shareholder Changes - Chen Ronghua reduced his holdings by 37,000 shares from September 22 to 29, representing a change of 0.0092% [1] - After this reduction, Chen Ronghua, through Shenzhen Nawei and Suzhou Naha, holds a total of 20,189,661 shares, accounting for 4.9997% of the total share capital [1] - This change does not trigger a mandatory takeover bid and does not lead to changes in the company's controlling shareholder or actual controller [1] Future Plans - The reduction in holdings is part of a previously announced plan, which has not yet been fully executed as of the announcement date [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Viewpoints - The acquisition of Metsera by Pfizer, valued at approximately $4.9 billion, underscores the significant potential and long-term growth prospects of the weight loss drug market, particularly in the GLP-1 segment [2][24]. - The report emphasizes the urgent demand for next-generation therapies, such as oral formulations and multi-target drugs, indicating a competitive landscape in the global GLP-1 research race [2][24]. - The Chinese weight loss drug industry is poised for growth, with a focus on companies that demonstrate strong sales execution and advanced research capabilities [3][24]. Summary by Sections Market Review - The pharmaceutical and biotechnology index fell by 2.20%, underperforming the CSI 300 index by 3.27 percentage points, ranking 24th among 31 sub-industries [1][16]. Key Company Insights - Companies to watch include Innovent Biologics (H), Heng Rui Medicine, Borui Medicine, Zhongsheng Pharmaceutical, Nawei Technology, WuXi AppTec (A+H), and Kelaiying (A+H) as they are expected to benefit from the expanding GLP-1 industry chain [3][24]. Annual Investment Strategy - The report suggests a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: hospital payments, out-of-pocket payments, and overseas payments [25]. - Key areas of interest include hospital policy support for innovative drugs and devices, expanding public demand for blood products, home medical devices, and the weight loss drug industry chain [25]. Company Earnings Forecast and Valuation - The report provides earnings per share (EPS) and price-to-earnings (PE) ratios for key companies, indicating a "Buy" rating for WuXi AppTec and Innovent Biologics, and an "Overweight" rating for Heng Rui Medicine [4]. Market Trends - The global weight loss drug market is experiencing rapid growth, with Pfizer's acquisition of Metsera highlighting the increasing market space associated with obesity-related health issues [28]. - The report notes that the commercialization of domestic weight loss drugs will hinge on sales capabilities and research advancements [3][24]. Important Company Announcements - Recent announcements include clinical trial updates and new drug applications from various companies, indicating ongoing innovation and development within the sector [27]. Financial Data - The basic medical insurance income for the first seven months of 2025 reached 1,684.7 billion yuan, with expenditures amounting to 1,369.7 billion yuan, reflecting the financial landscape impacting the pharmaceutical industry [30]. Price Trends - The report notes a decline in antibiotic prices and stability in cardiovascular raw material drug prices, which may influence the cost structure for pharmaceutical companies [36][43]. Conclusion - The report presents a positive outlook for the pharmaceutical and biotechnology sector, particularly in the weight loss drug market, driven by significant acquisitions and a growing demand for innovative therapies [2][24].

Market Overview - The chemical pharmaceutical sector increased by 0.39% on September 25, with Aosaikang leading the gains [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Top Gainers in Chemical Pharmaceutical Sector - Aosaikang (002755) closed at 23.28, up 10.02% with a trading volume of 126,300 shares and a turnover of 286 million [1] - Guangshengtang (300436) closed at 121.57, up 9.37% with a trading volume of 235,500 shares and a turnover of 2.802 billion [1] - Naimi Technology (688690) closed at 27.99, up 6.02% with a trading volume of 94,700 shares and a turnover of 26.1 million [1] Top Losers in Chemical Pharmaceutical Sector - Mengke Pharmaceutical (688373) closed at 8.61, down 10.96% with a trading volume of 717,800 shares [2] - Borui Pharmaceutical (688166) closed at 66.41, down 8.40% with a trading volume of 239,000 shares [2] - Haichen Pharmaceutical (300584) closed at 57.90, down 5.95% with a trading volume of 103,000 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 858 million from institutional investors, while retail investors saw a net inflow of 538 million [2] - The top stocks by net inflow from institutional investors included Guangshengtang with 325 million and Aosaikang with 97.5934 million [3] - Retail investors showed significant interest in Aosaikang, with a net outflow of 66.8017 million [3]

Investment Rating - The industry rating is "Overweight" (maintained) [5] Core Insights - The collaboration between Maiwei Biotech, Yingsi Intelligent, and Haoyuan Pharmaceutical aims to create a novel ADC (Antibody-Drug Conjugate) compound library covering hundreds of targets, accelerating the industrialization of next-generation ADC drugs, which are considered a promising direction in cancer treatment [5][6] - This partnership highlights a shift in China's pharmaceutical innovation model from a singular "independent R&D" approach to a more collaborative ecosystem that integrates strategic alliances and shared research platforms, which helps mitigate early-stage R&D risks and optimizes resource allocation [7] Summary by Sections Recent Industry Performance - Over the past 12 months, the industry has shown a relative return of 5.97% compared to the CSI 300 index, with an absolute return of 42.2% [3] Investment Highlights - The collaboration combines strengths from various fields: Maiwei Biotech's experience in antibody drug development, Yingsi Intelligent's AI technology for target discovery and molecular design, and Haoyuan Pharmaceutical's expertise in high-end chemical raw materials [7] - The ADC drugs are positioned in a rapidly growing global market, with the collaboration aiming to systematically lay out core resources for future ADC drug development [7] - The report suggests monitoring the capital market movements of the collaborating companies, as their progress may act as a catalyst for stock price changes [7] Recommendations - The report recommends focusing on the entire ADC industry chain, including upstream CXO companies with advanced toxin-Linker technology, midstream innovative pharmaceutical companies with leading ADC platforms, and downstream large pharmaceutical companies with strong commercialization capabilities in oncology [7] - Specific companies to watch include Maiwei Biotech, Haoyuan Pharmaceutical, Rongchang Biotech, WuXi AppTec, Kailaiying, Nanfeng Technology, and Dongfulong [7]

Group 1 - The core viewpoint emphasizes the strategic importance of new materials in driving the green transformation of traditional industries and fostering new productive forces, with Lanzhou Lanshi Zhongke Nano Technology Co., Ltd. emerging as a notable player in this field [1] - The company has achieved a breakthrough in the continuous and large-scale preparation of nano materials at normal temperature and pressure, overcoming the limitations of traditional batch production methods in terms of efficiency, cost, and environmental impact [2] - Lanzhou Lanshi Zhongke has established multiple production lines, including an annual output of 4,000 tons of nano magnesium hydroxide, 4,000 tons of magnesium-aluminum hydrotalcite, 5,000 tons of nano zinc oxide, and 1,500 tons of nano lithium iron phosphate precursor materials, achieving industry-leading standards in particle size control, dispersion, and batch stability [2] Group 2 - The company aligns with national strategies and aims to list on the Sci-Tech Innovation Board, which has become a preferred platform for hard-tech enterprises, supported by recent policies that enhance inclusivity for technology companies [3] - Lanzhou Lanshi Zhongke plans to submit its IPO application by the end of 2027, leveraging capital market opportunities to accelerate technological iteration and expand production capacity [3] - The company occupies a unique position in the resource recycling and new materials intersection, providing irreplaceable value in promoting low-carbon transformation in traditional industries, with no direct competitors in the A-share market [4] Group 3 - The national focus on green technology and new materials under the "dual carbon" goals has led to increased support for companies like Lanzhou Lanshi Zhongke, which reduces production energy consumption and costs while aiding downstream enterprises in resource recycling [5] - Guotai Junan Securities is set to provide comprehensive capital services for the company’s upcoming issuance, ensuring strong support for its market entry [5] - The growth trajectory of Lanzhou Lanshi Zhongke reflects the transformation and upgrading of Chinese SMEs through technological innovation, positioning it as a benchmark enterprise in the new materials sector [8]

Core Viewpoint - Nanwei Technology experienced a decline of 5.01% on September 23, with a stock price of 25.42 yuan per share and a total market capitalization of 10.265 billion yuan [1] Company Overview - Nanwei Technology, established on October 22, 2007, and listed on June 23, 2021, is located in Suzhou Industrial Park, Jiangsu Province. The company specializes in the research, large-scale production, sales, and application services of high-performance nano microsphere materials [1] - The main business revenue composition includes: 57.62% from chromatography fillers and chromatography media products, 19.72% from chromatography analysis instruments and accessories, 10.44% from liquid chromatography columns and sample pretreatment products, 5.02% from protein chromatography systems and accessories, 3.98% from microsphere products for optoelectronic fields, 1.35% from other products, 1.02% from separation and purification technology services, 0.78% from core microsphere products for IVD, and 0.06% from other supplementary products [1] Fund Holdings - According to data, one fund under Huatai PineBridge holds a significant position in Nanwei Technology. The Huatai PineBridge Science and Technology Innovation Board 2-Year Open Mixed Fund (506006) held 1.0052 million shares in the second quarter, accounting for 1.79% of the fund's net value, ranking as the tenth largest holding [2] - The fund has a current scale of 1.285 billion yuan and has achieved a return of 27.47% year-to-date, ranking 3368 out of 8172 in its category. Over the past year, it has returned 75.98%, ranking 1457 out of 7995, and since inception, it has returned 18.32% [2] Fund Manager Information - The fund manager of Huatai PineBridge Science and Technology Innovation Board 2-Year Open Mixed Fund (506006) is Xia Zheng'an, who has been in the position for 2 years and 343 days. The total asset scale of the fund is 1.418 billion yuan, with the best fund return during the tenure being 35.05% and the worst being 17.35% [3]

Core Viewpoint - Nanwei Technology emphasizes the increasing importance of innovative process research and domestic substitution of key materials in the blood products sector, aligning with the company's strategic focus on chromatography fillers as a core business direction [1] Group 1 - The company has identified blood products as one of the key application directions in its chromatography filler core business strategy, categorized as "3+2" [1] - Nanwei Technology is actively developing new products and application processes to meet customer demands in the blood products market [1] - The company has initiated various R&D projects at different stages to enhance its offerings in the blood products sector [1]